Bristol Myers Squibb Launches Inaugural China Collaboration Week to Drive Innovation and Partnerships for Patients

Committed to becoming an innovation leader "rooted in China, originating from China"

ShanghaiOctober 24, 2023PR Newswire -- Bristol-Myers Squibb announced the official opening of its first "China Collaboration Week" on October 23, with the event running until October 27.

"China Cooperation Week" is one of the key events organized by Bristol-Myers Squibb to promote business expansion, aiming to collaborate with China's leading biopharmaceutical and biotechnology companies as well as investors to explore innovative partnership opportunities. At the same time, this event marks an important milestone in Bristol-Myers Squibb’s "China 2030 Strategy," accelerating R&D innovation in fields such as oncology, hematology, immunology, fibrosis, cardiovascular, and neuroscience through close collaboration with local research institutions and innovative enterprises, providing breakthrough therapies for more patients with serious diseases.

"As a global leading biopharmaceutical enterprise, innovation and collaboration are not only at the core of Bristol-Myers Squibb's global strategy but also crucial to the company’s future development. In China and globally, we consistently seek the best scientific and innovative resources both internally and externally to build a highly promising product pipeline for the company."Jie Liu, Senior Vice President of Oncology, Hematology and Cell Therapy Business Development at Bristol-Myers Squibb (Jie D'Elia）"In the rapidly developing landscape of the global biopharmaceutical industry, China has become an indispensable and dynamic player. We firmly believe that the thriving growth of China’s biopharmaceutical industry is not just a Chinese story, but will also bring global influence. Through deepening local collaborations, we are confident in leading innovation and creating value together, accelerating the translation from basic research to clinical development, and bringing more innovative therapies to patients in China and around the world more quickly."

During the "China Cooperation Week," the "Bristol-Myers Squibb 2023 China Cooperation Forum," an important component to strengthen internal and external interactions and promote strategic cooperation, was successfully held on October 24. Nearly a hundred representatives from pharmaceutical, biotechnology, and venture capital companies attended the forum.

"The Chinese market is an important growth engine for Bristol-Myers Squibb's global business. Currently, we are accelerating the implementation of the company's 'China 2030 Strategy,' and are committed to becoming an innovation leader 'rooted in China, originating from China.'"Ms. Chen Siyuan, Vice President of Bristol-Myers Squibb, General Manager of China and Asian Regional Markets, and President of Bristol-Myers Squibb China"We remain steadfast in our commitment to China. Looking ahead, we will continue to collaborate with local partners from all sectors to promote innovation and development, aiming to bring more innovative medicines to patients in China and around the world more quickly, and to better 'protect the guardians of life.'"